Published in J Virol on November 01, 1987
Retracted Infectious measles virus from cloned cDNA. EMBO J (1990) 2.36
Transcription of human respiratory syncytial virus genome RNA in vitro: requirement of cellular factor(s). J Virol (1992) 1.56
Transcription inhibition and other properties of matrix proteins expressed by M genes cloned from measles viruses and diseased human brain tissue. J Virol (1994) 1.42
Germiston virus transcriptase requires active 40S ribosomal subunits and utilizes capped cellular RNAs. J Virol (1992) 1.36
Host RNA polymerase requirements for transcription of the human hepatitis delta virus genome. J Virol (2001) 1.21
Human parainfluenza virus type 3 transcription in vitro: role of cellular actin in mRNA synthesis. J Virol (1991) 1.20
The relationship between viral RNA, myelin-specific mRNAs, and demyelination in central nervous system disease during Theiler's virus infection. Am J Pathol (1990) 1.20
Characterization of an in vitro system for the synthesis of mRNA from human parainfluenza virus type 3. J Virol (1990) 1.19
Synthesis of leader RNA and editing of the P mRNA during transcription by purified measles virus. J Virol (1991) 1.02
Measles virus C protein interferes with Beta interferon transcription in the nucleus. J Virol (2011) 1.01
In vitro capping and transcription of rhabdoviruses. Methods (2012) 0.85
Phosphorylation of measles virus nucleoprotein affects viral growth by changing gene expression and genomic RNA stability. J Virol (2013) 0.81
Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350. Open Virol J (2012) 0.78
Newly identified minor phosphorylation site threonine-279 of measles virus nucleoprotein is a prerequisite for nucleocapsid formation. J Virol (2013) 0.76
Establishment of an in vitro transcription system for Peste des petits ruminant virus. Virol J (2012) 0.76
Nipah and Hendra Virus Nucleoproteins Inhibit Nuclear Accumulation of STAT1 and STAT2 by Interfering with Their Complex Formation. J Virol (2017) 0.75
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci U S A (1980) 109.70
Ribonucleic acid synthesis of vesicular stomatitis virus, II. An RNA polymerase in the virion. Proc Natl Acad Sci U S A (1970) 11.83
Sequential transcription of the genes of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1976) 5.88
Isolation of measles virus from cell cultures of brain from a patient with subacute sclerosing panencephalitis. N Engl J Med (1969) 4.76
Subacute sclerosing panencephalitis: isolation of measles virus from a brain biopsy. Nature (1969) 4.49
Complete transcription by the transcriptase of vesicular stomatitis virus. J Virol (1971) 4.12
Properties of the product synthesized by vesicular stomatitis virus particles. J Mol Biol (1971) 3.55
Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus. J Virol (1979) 3.54
Ribonucleic acid polymerase in virions of Newcastle disease virus: comparison with the vesicular stomatitis virus polymerase. J Virol (1971) 3.34
Comparison of the ribonucleic acid polymerases of two rhabdoviruses, Kern Canyon virus and vesicular stomatitis virus. J Virol (1971) 3.26
Determination of the complete nucleotide sequence of the Sendai virus genome RNA and the predicted amino acid sequences of the F, HN and L proteins. Nucleic Acids Res (1986) 2.60
Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc Natl Acad Sci U S A (1986) 2.45
Intracellular synthesis of measles virus-specified polypeptides. J Virol (1978) 2.21
A comparison of the polypeptides of four measles virus strains. Virology (1977) 2.15
Regulation of Sendai virus transcription: evidence for a single promoter in vivo. J Virol (1977) 2.02
Expression of defective measles virus genes in brain tissues of patients with subacute sclerosing panencephalitis. J Virol (1986) 1.84
Ribonucleic acid transcriptases in Sendai Virions and infected cells. J Virol (1971) 1.84
Primary in vivo transcription of vesicular stomatitis virus and temperature-sensitive mutants of five vesicular stomatitis virus complementation groups. J Virol (1973) 1.82
Ribonucleic acid polymerase activity in Sendai virions and nucleocapsid. J Virol (1971) 1.71
Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med (1984) 1.50
Alterations in expression of measles virus polypeptides by antibody: molecular events in antibody-induced antigenic modulation. J Immunol (1980) 1.45
Measles virus nucleotide sequences: detection by hybridization in situ. Science (1981) 1.45
Inhibition of vesicular stomatitis virus transcriptase complex by the virion envelope M protein. Biochem Biophys Res Commun (1979) 1.27
Inhibitor of vesicular stomatitis virus transcriptase in purified virions. Nature (1974) 1.26
Stimulation of vesicular stomatitis virus in vitro RNA synthesis by microtubule-associated proteins. Proc Natl Acad Sci U S A (1986) 1.26
Studies on the in vitro transcription and translation of vesicular stomatitis virus mRNA. Virology (1976) 1.26
Measles virus gene expression in subacute sclerosing panencephalitis. Virus Res (1984) 1.22
Purification of measles virus and characterization of subviral components. J Virol (1979) 1.20
Immune reactive measles virus polypeptides on the cell's surface: turnover and relationship of the glycoproteins to each other and to HLA determinants. J Immunol (1981) 0.98
Characterization of clones for the sixth (L) gene and a transcriptional map for morbilliviruses. J Gen Virol (1986) 0.97
Synthesis of VSV RNPs in vitro by cellular VSV RNPs added to uninfected HeLa cell extracts: VSV protein requirements for replication in vitro. Virology (1982) 0.95
Transcriptional map of the measles virus genome. J Gen Virol (1986) 0.95
Characterization of an RNA-dependent RNA polymerase activity associated with measles virus. J Virol (1978) 0.89
In vitro transcription of human pararotavirus. J Virol (1986) 0.86
Measles virus nucleic acid sequences in human brain. Virus Res (1986) 0.81
Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science (1985) 3.68
Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A (1983) 2.12
Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature (1979) 1.75
Two models for multiple sclerosis: experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus. J Neuropathol Exp Neurol (1996) 1.67
A neutralization-resistant Theiler's virus variant produces an altered disease pattern in the mouse central nervous system. J Virol (1989) 1.59
Mechanism of Theiler's virus-induced demyelination in nude mice. Lab Invest (1986) 1.53
Three-dimensional structure of Theiler virus. Proc Natl Acad Sci U S A (1992) 1.52
Infection with vaccinia favors the selection of hybridomas synthesizing autoantibodies against intermediate filaments, one of them cross-reacting with the virus hemagglutinin. J Immunol (1983) 1.46
Alterations in expression of measles virus polypeptides by antibody: molecular events in antibody-induced antigenic modulation. J Immunol (1980) 1.45
Apoptosis in acute and chronic central nervous system disease induced by Theiler's murine encephalomyelitis virus. Virology (1997) 1.41
Theiler's virus infection in nude mice: viral RNA in vascular endothelial cells. J Virol (1988) 1.41
Direct evidence of a role for amino acid 101 of VP-1 in central nervous system disease in Theiler's murine encephalomyelitis virus infection. J Virol (1991) 1.40
Alteration of amino acid 101 within capsid protein VP-1 changes the pathogenicity of Theiler's murine encephalomyelitis virus. J Exp Med (1989) 1.39
Viruses disrupt functions of human lymphocytes. II. Measles virus suppresses antibody production by acting on B lymphocytes. J Exp Med (1986) 1.24
Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B. J Virol (2001) 1.21
The relationship between viral RNA, myelin-specific mRNAs, and demyelination in central nervous system disease during Theiler's virus infection. Am J Pathol (1990) 1.20
Virus-induced immunosuppression: infection of peripheral blood mononuclear cells and suppression of immunoglobulin synthesis during natural measles virus infection of rhesus monkeys. J Infect Dis (1989) 1.19
Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. Brain Pathol (2000) 1.17
Failure to cleave measles virus fusion protein in lymphoid cells. J Exp Med (1981) 1.13
Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J Neuropathol Exp Neurol (1998) 1.11
Hydrocephalus in mice infected with a Theiler's murine encephalomyelitis virus variant. J Neuropathol Exp Neurol (1997) 1.09
Monoclonal antibody to Theiler's murine encephalomyelitis virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis. J Exp Med (1990) 1.08
Mapping of the major histocompatibility complex and viral antigens on the plasma membrane of a measles virus-infected cell. Virology (1983) 1.07
Viral infection and dissemination through the olfactory pathway and the limbic system by Theiler's virus. Am J Pathol (1993) 1.07
Importance of amino acid 101 within capsid protein VP1 for modulation of Theiler's virus-induced disease. J Virol (1994) 1.05
Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol (1999) 1.04
Restricted virus replication in the spinal cords of nude mice infected with a Theiler's virus variant. J Virol (1991) 1.03
Viruses can silently prime for and trigger central nervous system autoimmune disease. J Neurovirol (2001) 1.03
Membrane and cytoplasmic changes in virus-infected cells induced by interactions of antiviral antibody with surface viral antigen. Prog Med Virol (1980) 1.02
Protection of SJL/J mice from demyelinating disease mediated by Theiler's murine encephalomyelitis virus. Microb Pathog (1995) 1.00
Immune reactive measles virus polypeptides on the cell's surface: turnover and relationship of the glycoproteins to each other and to HLA determinants. J Immunol (1981) 0.98
Theiler's viruses with mutations in loop I of VP1 lead to altered tropism and pathogenesis. J Virol (1999) 0.98
Antigenic modulation induced by monoclonal antibodies: antibodies to measles virus hemagglutinin alters expression of other viral polypeptides in infected cells. J Immunol (1984) 0.97
Alterations in cytokine but not chemokine mRNA expression during three distinct Theiler's virus infections. J Neuroimmunol (2000) 0.96
Common immunologic determinant between human immunodeficiency virus type 1 gp41 and astrocytes. J Virol (1991) 0.96
Pathogenesis of Theiler's murine encephalomyelitis virus. Adv Virus Res (1991) 0.95
Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol (1993) 0.94
Molecular mimicry: a mechanism for autoimmune injury. FASEB J (1992) 0.93
Viruses as triggers of autoimmunity: facts and fantasies. Curr Opin Microbiol (1999) 0.91
Measles virus infection of human T cells modulates cytokine generation and IL-2 receptor alpha chain expression. Virology (1997) 0.91
Purification of measles virus glycoproteins and their integration into artificial lipid membranes. J Gen Virol (1981) 0.91
Serologic relatedness between Thy-1.2 and actin revealed by monoclonal antibody. J Immunol (1983) 0.89
DNA vaccination against Theiler's murine encephalomyelitis virus leads to alterations in demyelinating disease. J Virol (1999) 0.88
Experimental allergic encephalomyelitis in suckling Lewis rats: comparison with the disease in adult animals. Lab Invest (1977) 0.87
Cellular transfer of experimental allergic encephalomyelitis employing suckling and adult Lewis rats. J Clin Lab Immunol (1981) 0.87
Suppression of antigen-specific T cell proliferation by measles virus infection: role of a soluble factor in suppression. Virology (1998) 0.86
Induction of experimental allergic encephalomyelitis in suckling Lewis rats: role of age and type of sensitizing neuroantigen. J Immunol (1977) 0.86
Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine (1999) 0.85
Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infection. J Neuroimmunol (1998) 0.85
Contrasting effects of anti-adhesion molecule therapy in experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis. J Neuroimmunol (1999) 0.83
Antigenic mimicry between measles virus and human T lymphocytes. J Infect Dis (1987) 0.83
Gender variations in early Theiler's virus induced demyelinating disease: differential susceptibility and effects of IL-4, IL-10 and combined IL-4 with IL-10. J Neuroimmunol (1998) 0.83
Effects of regional spinal X-irradiation on demyelinating disease caused by Theiler's virus, mouse hepatitis virus or experimental allergic encephalomyelitis. J Neuroimmunol (1987) 0.83
Antisense-mediated resistance to measles virus infection in HeLa cells. J Infect Dis (1997) 0.82
Enhancement of EAE and induction of autoantibodies to T-cell epitopes in mice infected with a recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol (1997) 0.82
Virus encoding an encephalitogenic peptide protects mice from experimental allergic encephalomyelitis. J Neuroimmunol (1996) 0.82
B-lymphocyte requirement for vaccine-mediated protection from Theiler's murine encephalomyelitis virus-induced central nervous system disease. J Virol (1995) 0.82
Myelin basic protein serum factor. An endogenous neuroantigen influencing development of experimental allergic encephalomyelitis in Lewis rats. J Exp Med (1978) 0.82
Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic relapsing-remitting experimental allergic encephalomyelitis. J Neuroimmunol (1999) 0.81
MBP-SF, a prominent serum factor in suckling Lewis rats that additively inhibits the primary binding of myelin basic protein (MBP) to syngeneic anti-MBP antibodies. Immunochemistry (1978) 0.80
Peripheral nerve protein, P0, as a potential receptor for Theiler's murine encephalomyelitis virus. J Neurovirol (2001) 0.80
Antigenic modulation: a mechanism of viral persistence. Prog Brain Res (1983) 0.79
Immunologic determinants of experimental neurologic autoimmune disease and approaches to the multiple sclerosis problem. Trans Am Clin Climatol Assoc (1978) 0.79
Rapid accumulation of measles virus leader RNA in the nucleus of infected HeLa cells and human lymphoid cells. J Virol (1991) 0.78
Theiler's murine encephalomyelitis virus contrasts with encephalomyocarditis and foot-and-mouth disease viruses in its functional utilization of the StopGo non-standard translation mechanism. J Gen Virol (2012) 0.77
Immune responses against myelin basic protein and/or galactocerebroside cross-react with viruses: implications for demyelinating disease. Curr Top Microbiol Immunol (1989) 0.77
Lack of correlation of Theiler's virus binding to cells with infection. J Neurovirol (1997) 0.77
Lack of suppressive effect of alpha-foetoprotein on development of experimental allergic encephalomyelitis in rats. Nature (1977) 0.75
Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein. J Neuroimmunol (1993) 0.75
Immunity to viruses. Curr Opin Immunol (1990) 0.75
DNA immunization and central nervous system viral infection. Adv Virus Res (2001) 0.75
Characterization of a murine central nervous system-derived cell line: infectability and presentation of viral antigen. J Neuroimmunol (1994) 0.75
Immunity to viruses. Curr Opin Immunol (1989) 0.75